BOISE, Idaho, April 14, 2016 -- Micron Technology, Inc. (NASDAQ:MU) today announced that it intends to offer, subject to market and other considerations, $1 billion aggregate principal amount of senior secured notes due 2023 (the “Notes”) through an offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.
Micron intends to use the net proceeds from the offering for general corporate purposes, including to fund capital expenditures, working capital, and to pay related fees and expenses.
The notes will be senior secured obligations of Micron and are expected to be guaranteed by one of Micron’s domestic subsidiaries. The interest rate, redemption provisions and other terms of the Notes will be determined by negotiations between Micron and the initial purchasers.
This announcement does not constitute an offer to sell or a solicitation of an offer to buy any of the foregoing securities, nor shall there be any offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.
The Notes have not been and will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.
Contacts: Ivan Donaldson Investor Relations [email protected] (208) 368-4093 Daniel Francisco Media Relations [email protected] (208) 368-5584


7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Italy Fines Apple €98.6 Million Over App Store Dominance
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
FDA Approves Mitapivat for Anemia in Thalassemia Patients
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 



